Cargando…
Real-world treatment outcomes with halobetasol propionate 0.01%/tazarotene 0.045% lotion in patients with mild-to-moderate plaque psoriasis: A Canadian multicenter retrospective chart review
Autores principales: | Vender, Ronald, Turchin, Irina, Lansang, Perla, Prajapati, Vimal H., Legault, Mark, Barakat, Maxime, Yeung, Jensen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204718/ https://www.ncbi.nlm.nih.gov/pubmed/35721301 http://dx.doi.org/10.1016/j.jdin.2022.05.001 |
Ejemplares similares
-
Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults
por: Reddy, Vidhatha, et al.
Publicado: (2020) -
Erbium-doped (Pb(0.9)-Er(0.01)-Zr(0.09)) and (Pb(0.9)-Er(0.01)-Zr(0.045)-Ti(0.045)) nano-crystalline films and nano-rods ceramic synthesis by sol–gel technique for energy-storage application
por: Ibrahim, F. A., et al.
Publicado: (2023) -
Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits
por: Lebwohl, Mark G., et al.
Publicado: (2021) -
Lupoid cutaneous leishmaniasis in Afghanistan treated with 0.045% DAC N-055
por: Stahl, KW, et al.
Publicado: (2011) -
0.045% DAC N-055 a choice for poor Afghan surgical patients?
por: Stahl, KW, et al.
Publicado: (2011)